What are the future ramifications to Pharma Marketers.

F.D.A. Deal Allows Amarin to Promote Drug for Off-Label Use

Read here:

http://www.nytimes.com/2016/03/09/business/fda-deal-allows-amarin-to-promote-drug-for-off-label-use.html?_r=0

Considering the FDA denotes this is a special case it still opens pandora's box of off label marketing of ethical pharmaceuticals as long as they are within truthful statements of the appicable clinical study. It will be interesting to see the developments from this action.